Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation (TAILOR)
Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase-producing Enterobacterales Undergoing Liver Transplantation: a Stepped Wedge Cluster Randomization Trial
This is a multicenter stepped-wedge cluster randomized trial, conducted over a 2-year period at three hospitals. The trial is structured into four phases, each lasting six months. During phase 1 (pre-rollout), all hospitals will use standard antibiotic prophylaxis for all patients. In each of phases 2 to 4, one hospital will switch to targeted antibiotic prophylaxis, so that by phase 4 all hospitals will be using it. The order in which hospitals switch is determined by computer-generated randomization performed centrally by an independent statistician, ensuring each hospital has an equal chance of switching at any given phase and minimizing selection bias.
The goal of this clinical trial is to learn whether targeted antibiotic prophylaxis works better than standard antibiotic prophylaxis at preventing infections in liver transplant patients who carry resistant bacteria called CPE (carbapenemase-producing Enterobacterales). It will also learn about the effects of these antibiotics on gut bacteria.
The main questions it aims to answer are:
- Does targeted antibiotic prophylaxis reduce the number of CPE infections occurring in the first two weeks after liver transplant, compared to standard prophylaxis?
- How do targeted and standard antibiotic prophylaxis affect the gut microbiome after transplant?
- Is there a link between achieving optimal antibiotic blood levels and the risk of developing an infection after transplant?
Researchers will compare targeted antibiotic prophylaxis (chosen based on the specific bacteria each patient carries) to standard antibiotic prophylaxis (used routinely at each hospital) to see which approach better prevents infection.
This study does not involve the administration of any drugs or instrumental examinations beyond those already part of standard clinical care at each center. However, additional blood tests will be performed by collecting one extra blood sample (and a bile sample, if the patient has a Kehr's tube, which is a drain placed in the bile duct after surgery) during blood draws already scheduled as part of routine clinical practice, in order to measure drug levels in the blood. Stool samples will also be collected specifically for the study to investigate the gut microbiome.
調査の概要
状態
詳細な説明
Colonization and infection with carbapenemase-producing Enterobacterales (CPE) have been associated with significant morbidity and mortality in the setting of solid organ transplantation (SOT), and in particular among liver transplant (LT) candidates and/or recipients. Indeed, the prevalence of CPE infection is highest after LT compared with other types of SOT, CPE carriage is the strongest predisposing factor, and CPE carriage/infection has been associated with significant increase in the odds of death across multiple studies. Several strategies have been proposed to reduce CPE infection and associated poor outcome after LT, including active screening, decolonization and targeted perioperative antibiotic prophylaxis (T-PAP). Decolonization is no longer recommended due to its limited benefit and associated adverse events, observed also in a randomized controlled trial on SOT recipients. Recent European guidelines endorsed the performance of active screening for CPE carriage before LT but, due to the lack of evidence, they could not provide a recommendation regarding optimal PAP in CPE carriers. This study addresses a critical unmet need in liver transplantation by evaluating targeted perioperative antibiotic prophylaxis (T-PAP) versus standard perioperative antibiotic prophylaxis (S-PAP) in CPE colonized patients. By using a stepped-wedge cluster-randomized design, it could generate robust, practice-changing evidence on how to reduce early CPE infections, mortality, and healthcare costs. The project is innovative in study design as well as in integrating advanced gut microbiome (GM) and resistome analyses, offering new insights into the GM effects of perioperative antibiotic strategies. The use of therapeutic drug monitoring (TDM) to optimize dosing adds a precision medicine approach. Findings are expected to impact clinical guidelines and improve outcomes for transplant recipients and potentially for other high-risk surgical populations.
The stepped-wedge design is better suited than standard individual randomization for evaluating the potential indirect effects of the T-PAP policy on gut microbiome and liver functionality.
The intervention will consist of targeted perioperative antibiotic prophylaxis (T-PAP) using an agent shown to be active in vitro against the colonizing strain. The specific drug will be selected at the discretion of the local investigator, in collaboration with the attending physician, and, if necessary, discussed with all the study investigators in a dedicated meeting. In the control arm, standard perioperative antibiotic prophylaxis (S-PAP) will be administered according to local protocols. In both arms, prophylaxis will begin 30-60 minutes before surgical incision, following guidelines, and will be discontinued no later than 48 hours post-surgery.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前：Maddalena Giannella, MD, PhD
- 電話番号：+39 051 2143199
- メール：maddalena.giannella@unibo.it
研究連絡先のバックアップ
- 名前：Matteo Rinaldi, MD
- 電話番号：+39 051 2143595
- メール：matteo.rinaldi@aosp.bo.it
研究場所
-
-
BO
-
Bologna、BO、イタリア、40138
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
-
コンタクト：
- Maddalena Giannella, MD, PhD
- 電話番号：+39 051 2143199
- メール：maddalena.giannella@unibo.it
-
コンタクト：
- Matteo Rinaldi, MD
- 電話番号：+39 051 2143595
- メール：matteo.rinaldi@aosp.bo.it
-
副調査官：
- Matteo Rinaldi, MD
-
-
PI
-
Pisa、PI、イタリア、56126
- Azienda Ospedaliero Universitaria Pisana
-
コンタクト：
- Marco Falcone, MD
- 電話番号：0039 050 996735
- メール：marco.falcone@unipi.it
-
-
TO
-
Torino、TO、イタリア、10126
- Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
-
コンタクト：
- Silvia Corcione, MD, PhD
- 電話番号：+39 0116705466
- メール：silvia.corcione@unito.it
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Adult (≥18 years) patients colonized with Carbapenemase-Producing Enterobacterales (CPE) undergoing liver transplantation (LT)
- Informed consent signed by the enrolled patients
Exclusion Criteria:
- Active infection from any Gram-negative bacteria at the time of LT
- High risk of donor-derived CPE infection (e.g., donors known to be colonized or infected with CPE at the time of death, or CPE isolated from donor blood or preservation fluid samples)
- Hypersensitivity to the active substance or to any of the excipients
- Pregnancy and breastfeeding
- Participation in a clinical trial in which an investigational drug was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer.
- History of severe immediate hypersensitivity reactions (e.g., anaphylaxis) to beta-lactam agents (e.g., cephalosporins, carbapenems, or monobactams).
- Colonization by strains resistant to all Investigational Medicinal Products (IMPs)
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：クロスオーバー割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Targeted prophylaxis T-PAP
Patients included in the Targeted prophylaxis (T-PAP) arm will be treated using an agent shown to be active in vitro against the colonizing strain. The specific drug will be selected at the discretion of the local investigator, in collaboration with the attending physician, and, if necessary, discussed with all the study investigators in a dedicated meeting.All drugs will be used strictly in accordance with their approved Summary of Product Characteristics (SmPC). Available drugs that could be used as a T-PAP are:
|
2g/0.5g powder for concentrate for solution for infusion.Each vial contains ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam.
For T-PAP, the administration should not exceed 48 hours
1g/1g powder for concentrate for solution for infusion.
Each vial contains meropenem trihydrate equivalent to 1 g meropenem, and 1 g vaborbactam.
Excipient with known effect: Each vial contains 10.9 mmol of sodium (approximately 250 mg).
For T-PAP, the administration should not exceed 48 hours.
Supplied as a dry powder in a single-dose vial that must be constituted and further diluted using aseptic technique prior to intravenous infusion (IV). Each vial contains imipenem monohydrate equivalent to 500 mg imipenem, cilastatin sodium equivalent to 500 mg cilastatin, and relebactam monohydrate equivalent to 250 mg relebactam. For T-PAP, the administration should not exceed 48 hours.
Supplied as single use vials containing cefiderocol sodium tosylate, equivalent to 1 g cefiderocol.
Excipients include sucrose, sodium chloride and sodium hydroxide.
For T-PAP, the administration should not exceed 48 hours.
Supplied as a single use vials containing sterile solution of Aztreonam and Arginine and a suitable osmolality adjusting substance in Water for Injection.
It contains NLT 90.0% and NMT 120.0% of the labeled amount of aztreonam.
For T-PAP, the administration should not exceed 48 hours.
Supplied as powder for concentrate for solution for infusion, each vial contains 50 mg of eravacycline.
Each vial is for single use only, that must be reconstituted and further diluted using aseptic technique prior to intravenous infusion.
For T-PAP, the administration should not exceed 48 hours.
Supplied as powder for concentrate for solution for infusion, each vial contains 1.5 g of aztreonam and avibactam sodium equivalent to 0.5 g of avibactam.
For T-PAP, the administration should not exceed 48 hours.
|
|
実験的：Standard prophylaxis S-PAP
Patients include in the Standard prophylaxis (S-PAP) arm will be treated with standard drugs administered according to local protocols. Drugs used as S-PAP are:
|
Powder for solution for injection or infusion, supplied as vials of 2000/200 mg.
Each vial contains 2000 mg amoxicillin (as amoxicillin sodium) and 200 mg clavulanic acid (as potassium clavulanate).
Each vial contains 5.5 mmol (125.9 mg) of sodium and 1 mmol (39.3 mg) of potassium.
For S-PAP, the duration should not exceed 48 hours.
Powder for solution, each vial contains amounts of Piperacillin Sodium and Tazobactam Sodium equivalent to not less than 90.0 percent and not more than 110.0 percent of the labeled amounts of piperacillin, the labeled amounts representing proportions of piperacillin to tazobactam is of 8 : 1.
It may contain small amounts of a suitable buffer stabilizer.
For S-PAP, the duration should not exceed 48 hours.
Powder for solution, each vial should be reconstituted with 5.3 mL of 0.9% Sodium Chloride Injection, or 5% Dextrose Injection, to achieve a concentration of 10 mg/mL of tigecycline.
For S-PAP, the duration should not exceed 48 hours.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To investigate the impact of T-PAP vs. S-PAP on the incidence of early CPE infection after LT in patients colonized with CPE undergoing LT
時間枠：Within 14 days after liver transplant
|
The impact of T-PAP over S-PAP will be calculated comparing the percentage of CPE infections in the first two weeks after LT in the intervention and control group.
|
Within 14 days after liver transplant
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To investigate the impact of T-PAP vs. S-PAP on the dynamics of gut microbiome after LT in patients colonized with CPE at transplant
時間枠：At the time of liver transplant, and at 14, 30, 60 and 90 days after liver transplant
|
Cross-sectional differences between T-PAP and S-PAP groups over time, in GM alpha diversity, composition (relative abundance at different taxonomic levels) and functionality (gene and pathway abundances), will be assessed using the Kruskal-Wallis test, followed by post-hoc Wilcoxon rank-sum tests.
|
At the time of liver transplant, and at 14, 30, 60 and 90 days after liver transplant
|
|
To investigate the relationship between the attainment of optimal pharmacokinetics/pharmacodynamics (PK/PD) target and the occurrence of CPE and non-CPE infections after LT in patients colonized with CPE at transplant
時間枠：Within 14 days from liver transplant
|
In order to evaluate the relationship between the attainment of early optimal PK/PD target with agents used for both T-PAP and S-PAP and the occurrence of CPE and non-CPE infections in the post-LT period, TDM of selected agents will be performed at the end of surgical procedure and at 24 hours after starting T-PAP and S-PAP.
The relationship between the attainment of optimal PK/PD target and the occurrence of CPE and non-CPE infections will be calculated comparing the percentage of patients developing CPE and non-CPE infections in the first two weeks after LT in the intervention and control group.
|
Within 14 days from liver transplant
|
|
To investigate the impact of T-PAP vs. S-PAP on CPE carriage status
時間枠：At 30, 60 and 90 days after liver transplant
|
The impact of T-PAP vs S-PAP on CPE carriage status will be calculated comparing the percentage of patients colonized with Carbapenem-producing Enterobacterales (CPE) at 30, 60 and 90 days after LT in the intervention and control group.
|
At 30, 60 and 90 days after liver transplant
|
|
To investigate the development of bacterial infections
時間枠：At 30, 60 and 90 days after liver transplant
|
The impact of T-PAP vs S-PAP will be calculated comparing the percentage of patients diagnosed with a bacterial infection at 30, 60 and 90 days after LT in the intervention and control group.
|
At 30, 60 and 90 days after liver transplant
|
|
To investigate all-cause mortality
時間枠：At 30, 60 and 90 days after liver transplant
|
The impact of T-PAP vs S-PAP will be calculated comparing the percentage of patients who died from any cause at 30, 60 and 90 days after LT in the intervention and control group.
|
At 30, 60 and 90 days after liver transplant
|
|
To investigate the safety of T-PAP versus S-PAP
時間枠：During prophylaxis administration or within 7 days from the initiation of administration
|
The rates of adverse events (e.g.
neurotoxicity) in the intervention and in the control groups will be computed.
|
During prophylaxis administration or within 7 days from the initiation of administration
|
協力者と研究者
捜査官
- 主任研究者：Maddalena Giannella, MD, PhD、IRCCS Azienda Ospedaliero-Universitaria di Bologna
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 硫黄化合物
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 医薬品準備
- 炭化水素
- 炭化水素、周期的
- 多環芳香族炭化水素
- 炭化水素、芳香
- 多環式化合物
- アミド
- ナフテセン
- テトラサイクリン
- 薬物の組み合わせ
- ペニシリンg
- ベータラクタム
- ラクタム
- クラブラン酸
- クラブラン酸
- セファロスポリン
- チアジン
- スルホン
- タゾバクタム
- ペニシラン酸
- ピペラシリン
- アンピシリン
- ペニシリン
- Monobactams
- アモキシシリン
- チゲサイクリン
- ピペラシリン、タゾバクタム配合剤
- セフィデロコル
- アモキシシリンとクラブラン酸カリウムの組み合わせ
- アズトレオナム
- Avibactam、Ceftazidime Drugの組み合わせ
- MeropenemとVaborbactam
- エラバシクリン
- イミペネム、シラスタチンおよびレレバクタム
その他の研究ID番号
- TAILOR
- 2025-523453-34-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。